delivertrial.org

Robots.txt Information

Robot	Path	Permission
GoogleBot	/	✔
BingBot	/	✔
BaiduSpider	/	✔
YandexBot	/	✔
User-agent: * Allow: / # Optimization for Google Ads Bot User-agent: AdsBot-Google-Mobile User-agent: AdsBot-Google Disallow: /_api/* Disallow: /_partials* Disallow: /pro-gallery-webapp/v1/galleries/* # Block PetalBot User-agent: PetalBot Disallow: / Sitemap: https://www.delivertrial.org/sitemap.xml # Auto generated, go to SEO Tools > Robots.txt Editor to change

Meta Tags

Title	Home \|
Description	The DELIVER trial was an international randomized trial comparing dapagliflozin to placebo in patients with heart failure with mildly reduced or preserved ejection
Keywords	N/A

Server Information

WebSite	delivertrial.org
Host IP	185.230.63.171
Location	-

Related Websites

                        Site
                        Rank
                    

More to Explore

delivertrial.org Valuation

US$1,194

Last updated: 2023-05-20 05:57:07

delivertrial.org has Semrush global rank of 0. delivertrial.org has an estimated worth of US$ 1,194, based on its estimated Ads revenue. delivertrial.org receives approximately 137 unique visitors each day. Its web server is located in -, with IP address 185.230.63.171. According to SiteAdvisor, delivertrial.org is safe to visit.

Traffic & Worth Estimates

Purchase/Sale Value	US$1,194
Daily Ads Revenue	US$1
Monthly Ads Revenue	US$33
Yearly Ads Revenue	US$396
Daily Unique Visitors	9
Note: All traffic and earnings values are estimates.

DNS Records

Host	Type	TTL	Data
delivertrial.org.	A	3599	IP: 185.230.63.171
delivertrial.org.	A	3599	IP: 185.230.63.186
delivertrial.org.	A	3599	IP: 185.230.63.107
delivertrial.org.	NS	86400	NS Record: ns1.wixdns.net.
delivertrial.org.	NS	86400	NS Record: ns0.wixdns.net.

HtmlToTextCheckTime:2023-05-20 05:57:07

top of page Home About DELIVER Team Publications Presentations News Contact Disclosures What was DELIVER? DELIVER was a randomized, placebo-controlled, double-blind international clinical outcomes trial testing the hypothesis that dapagliflozin compared with placebo would reduce the risk of cardiovascular death or worsening heart failure in patients with heart failure with mildly reduced or preserved ejection fraction. Patients were eligible if they had heart failure with LVEF > 40%, evidence of structural heart disease and elevated natriuretic peptides. Patients could be enrolled if ambulatory, hospitalized or recently hospitalized and patients with prior LVEF of 40% or less were eligible if their LVEF had improved to over 40% by enrollment. What did DELIVER show? DELIVER randomized 6263 patients with heart failure with mildly reduced or preserved ejection fraction to dapagliflozin or placebo and followed these patients for a median of 2.3 years. Vital status was known at the

HTTP Headers

HTTP/1.1 301 Moved Permanently
Date: Sun, 15 Jan 2023 09:14:46 GMT
Content-Length: 0
Connection: keep-alive
location: https://www.delivertrial.org/
strict-transport-security: max-age=3600
x-wix-request-id: 1673774086.195176457522922803
Age: 0
Server-Timing: cache;desc=miss, varnish;desc=miss, dc;desc=84
X-Seen-By: RQvnDyN5n1orR2cJk2hJbg==,sHU62EDOGnH2FBkJkG/Wx8EeXWsWdHrhlvbxtlynkViFk93xTl/k9ZxS+DN/1xRf,m0j2EEknGIVUW/liY8BLLiaqgLZ5wJhGoafsxbw4j/XJftmKrOReD3ukbbas4YDo,2d58ifebGbosy5xc+FRalu96ITATniX0FXsHgy8jL8wvy6lFvBJ37X0K/XT/zQldiIO/ZEek/p4AgXYiIcku8g==,2UNV7KOq4oGjA5+PKsX47AgwiXskEY9NBGhMxjF/VCG8ZDY613cHYLbuhNMgAom1,7npGRUZHWOtWoP0Si3wDp7zT5RIk4Gbggt5/mHmXvRE=,xTu8fpDe3EKPsMR1jrheECsFwI5O/8OMmehAyN9L8OU=,7qRhWu5NOm1hVs7o3HvocF74Z2UDAFbAlpDDQ+OnIcrggYVN+/jiTtGzIcs+jNA/Vnd8Z4jLK9R467MyhrzM6w==
Cache-Control: no-cache
X-Content-Type-Options: nosniff

HTTP/2 200 
date: Sun, 15 Jan 2023 09:14:46 GMT
content-type: text/html; charset=UTF-8
link: ; rel=preconnect; crossorigin;,; rel=preconnect;,; rel=preconnect; crossorigin;,; rel=preconnect;,; rel=preconnect; crossorigin;,
x-wix-request-id: 1673774086.37122431042817885
content-language: en
strict-transport-security: max-age=3600
age: 0
x-seen-by: GXNXSWFXisshliUcwO20NXdyD4zpCpFzpCPkLds0yMe/pJAowCp9L91E5yWR10DQ,qquldgcFrj2n046g4RNSVIrig9SAqnXW0O7zAzsQkQs=,2d58ifebGbosy5xc+FRalkywmBqwHEnu1VP/O/FbrbAjFwGYHiNHQWpZDM0TlUQxjoe2GMQJ/MdiMK4Y/vI70wC/kCWSfPJb20DZZ7+Q87U=,2UNV7KOq4oGjA5+PKsX47CaoqenxK2HVw7LGKSkCvFdYgeUJqUXtid+86vZww+nL,7npGRUZHWOtWoP0Si3wDp7zT5RIk4Gbggt5/mHmXvRE=,7qRhWu5NOm1hVs7o3HvocMT63kunpyoAts/2mWOoX5WSsxUrpN4CGQblKzIVw8iCiy9RDN50yNDYuMRjpFglRg==,xTu8fpDe3EKPsMR1jrheEJED/2UWJZIEQyXzbTkrI1o=,xTu8fpDe3EKPsMR1jrheEGVydzW83EOjzSir+9Eged4=,LoUK8/saGAmOxZWtpubo2m+uOos7EBEgJaJDZZG+gXqiGBsKFg0QH9f+xOvoZmehdSM4jVu05U8coqMB5gtTlg==,xTu8fpDe3EKPsMR1jrheEGVydzW83EOjzSir+9Eged4=,xTu8fpDe3EKPsMR1jrheEJmuyM2EC+bkcChb47KVmfM=,/a5ccLSK1HEmwPNg/x6OukIT+c5HqyHveWvXmN7dchqo1u460enq+xnsEyLRiMINsfeTgyl0Kkry+TQJuA4rT+G4bFrcD+oypFBtCgKHchQ=
cache-control: no-cache
vary: Accept-Encoding
accept-ranges: bytes
set-cookie: ssr-caching=cache#desc=miss#varnish=miss#dc#desc=euw3_g; Max-Age=20; Expires=Sun, 15 Jan 2023 09:15:06 GMT
server-timing: cache;desc=miss, varnish;desc=miss, dc;desc=euw3_g
x-content-type-options: nosniff
server: Pepyaka/1.19.10
via: 1.1 google
alt-svc: h3=":443"; ma=2592000,h3-29=":443"; ma=2592000,h3-Q050=":443"; ma=2592000,h3-Q046=":443"; ma=2592000,h3-Q043=":443"; ma=2592000,quic=":443"; ma=2592000; v="46,43"

delivertrial.org valuation and analysis